Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Oct 12;6:35316. doi: 10.1038/srep35316

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) miR-155 expression was regulated by VEGF in a time- and dose-dependent manner. (b) After stimulation with 50 ng/mL VEGF for 12 h, miR-155 significantly decreased in the group treated with ERK inhibitor compared with those treated with AKT inhibitor. That indicated that VEGF modulated miR-155 via the ERK signaling pathway. (c,d) Representative photomicrograph and quantification of microtubule formation, depicting effects of VEGF and miR-155 in HUVECs. Angiogenic function of HUVECs was proved to be positively correlated miR-155. Scale bars = 200 μm. (e,f) qPCR and Western blot analysis for the expression of VCAM-1, SDF-1 and IGF-1 in VEGF or pre-155 treatment groups in HUVECs. Pre-155 alone was found to render levels of proangiogenic cytokines, while inh-155 partially reversed VEGF-induced angiogenesis factors. All data are means ± SD. *P < 0.05.